

The Vasoselective Antihypertensive

V/M ratio = 100 : 1

No effect on myocardial contractility or cardiac conduction¹

Minimal effect on veins

Reduces the likelihood of orthostatic hypotension¹

Smooth and sustained control of hypertension¹

Regresses left ventricular hypertrophy²

References:

1. Clin. & Exper. Hype. Therapy & Practice 1992; A14(6): 965-988
2. Drugs 1987; 34(Suppl.3): 7-15

CIPLA – YOUR HEALTHCARE PARTNER SINCE 1935

Produced by **CIPLA**, a leading provider of generic pharmaceuticals.

Key Facts about CIPLA:

- 25 manufacturing facilities approved by leading regulatory authorities including the FDA (USA), MHRA (U.K.) and TGA (Australia).
- Over 1000 Formulations and 150 Active Pharmaceutical Agents.
- Prequalified and Approved by the World Health Organisation (WHO) for supply to UN Agencies.
- The World's largest range of antiasthmatic aerosols and inhalation devices.
- The World's largest manufacturer of antiretroviral drugs and supplier to the Clinton Foundation AIDS/HIV Initiative.